Men | Women | |||||||
---|---|---|---|---|---|---|---|---|
ACR (mg/g) | Q1 (0.5–6.8) | Q2 (6.9–12.5) | Q3 (12.6–26.3) | Q4 (≥26.4) | Q1 (0.5–6.8) | Q2 (6.9–12.5) | Q3 (12.6–26.3) | Q4 (≥26.4) |
N=35 470 | 4265 | 3682 | 2960 | 2820 | 4589 | 5264 | 5839 | 6051 |
Age (years) | 41.1 (40.4–41.9) | 42.8 (41.9–43.7)* | 45.2 (44.2–46.2)* | 48.3 (47.3–49.3)* | 41.6 (40.8–42.4) | 41.2 (40.5–42.0) | 43.2 (42.4–44.0)* | 47.6 (46.4–48.9)* |
Overweight | 26.8 (23.2–23.5) | 27.9 (23.4–23.8) | 29.0 (24.3–24.6)* | 33.1 (30.2–36.1)* | 19.9 (17.7–22.4)† | 23.6 (21.6–25.7)*† | 21.7 (20.0–23.5)† | 27.3 (25.1–29.7)*† |
Obese | 4.3 (3.1–6.0) | 5.5 (4.4–6.8)* | 4.5 (3.6–5.7) | 8.9 (7.3–10.9)* | 4.2 (3.3–5.3) | 3.3 (2.7–4.1)* | 3.9 (3.2–4.8) | 6.3 (5.2–7.5)*† |
Central obesity | 24.2 (22.0–26.6) | 24.8 (22.7–27.1) | 24.7 (22.3–27.3) | 31.9 (29.1–34.9)* | 34.6 (32.0–37.4)† | 34.8 (32.6–37.1)† | 36.7 (34.5–38.9)*† | 45.9 (42.8–48.9)*† |
HTG | 31.3 (31.0–33.8) | 29.7 (28.8–34.0) | 32.1 (29.3–35.0) | 38.0 (35.0–41.1)* | 21.1 (18.9–23.4)† | 18.9 (17.1–20.8)† | 20.6 (18.9–22.5)† | 27.0 (24.4–29.8)*† |
Hypertension | 15.8 (14.2–17.6) | 24.0 (21.8–26.3)* | 29.9 (27.2–32.7)* | 43.0 (39.9–46.3)* | 13.3 (11.4–15.5) | 12.5 (11.2–13.9)† | 19.5 (17.8–21.4)*† | 36.1 (33.0–39.4)*† |
IGR | 15.8 (13.7–18.1) | 17.2 (15.2–19.4) | 18.7 (16.4–21.2)* | 25.0 (22.3–27.8)* | 13.4 (11.7–15.2) | 13.8 (13.9–16.9)† | 15.4 (13.9–16.9)*† | 23.3 (20.4–26.4)* |
IR | 24.0 (21.8–26.4) | 24.7 (22.4–27.2) | 22.8 (20.4–25.4) | 30.1 (27.2–33.1)* | 22.5 (20.4–24.8) | 23.4 (21.5–25.5) | 24.0 (22.0–26.1) | 28.0 (25.6–30.5)* |
*p<0.05 vs ACR 0.5 to 6.8 mg/g.
†p<0.05 vs men at same ACR quartiles.
ACR, albumin/creatinine ratio; HTG, serum triglyceride ≥1.7 mmol/L; IGR, impaired glucose regulation, IR, insulin resistant.